Manage your formulary budget
Anticipate generic drug launch
Find generic entry opportunities
Drug patents …
… from Kazakhstan to Kalamazoo
Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Flat-rate pricing for predictable budgeting
Short-term plans for project- or client-based billing
|Title:||Terazosin monohydrochloride and processes and intermediate for its production|
|Abstract:||The present invention provides a non-solvated crystalline polymorph of terazosin monohydrochloride designated Form III and methods for its preparation. Also disclosed is terazosin monohydrochloride methanolate and processes for its production as well as processes for its conversion to other crystalline forms of terazosin monohydrochloride.|
|Inventor(s):||Morley; James A. (Gurnee, IL), Bauer; John F. (Lake Bluff, IL), Patel; Ramesh F. (Chicago, IL), Henry; Rodger E. (Waukegan, IL), Spanton; Stephen G. (Grayslake, IL)|
|Assignee:||Abbott Laboratories (Abbott Park, IL)|
Patent Claim Types:|
see list of patent claims
|Patent Number||Expiration Date|
|5,412,095||May 02, 2007|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|European Patent Office||0623612||► subscribe|
|European Patent Office||0622067||► subscribe|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.